Iverheal 6 mg (Ivermectin)

Iverheal 6mg (Ivermectin): Complete Medical Guide

 Iverheal 6mg is a prescription antiparasitic tablet containing Ivermectin 6mg as its active ingredient, manufactured by Healing Pharma India Pvt. Ltd. It is used to treat a broad range of parasitic infections affecting the intestinal tract, skin, and eyes — including strongyloidiasis, onchocerciasis (river blindness), lymphatic filariasis, and scabies. 

Ivermectin, the active molecule in Iverheal 6mg, belongs to the macrocyclic lactone class of antiparasitic medications. It is listed on the World Health Organization’s (WHO) List of Essential Medicines and is used in WHO-supported mass drug administration (MDA) programmes reaching hundreds of millions of people annually in endemic regions. Its co-discoverers, Satoshi Ōmura and William C. Campbell, were awarded the 2015 Nobel Prize in Physiology or Medicine for this discovery. 

Iverheal 6mg is the intermediate strength in the Iverheal range — situated between the 3mg tablet (for lower body weight patients) and the 12mg tablet (for higher body weight or more severe infections). This strength is typically prescribed for patients in the 25–44 kg body weight range for standard antiparasitic indications, with dosage always determined by the treating healthcare provider based on the patient’s weight and clinical condition. 

Important: Iverheal 6mg is a prescription-only medication. It must not be used for self-medication, and it is not approved or recommended for the treatment of COVID-19 outside of formally supervised clinical research studies. 

What is Iverheal 6mg? 

Iverheal 6mg is a brand-name oral tablet containing 6 milligrams of Ivermectin, produced by Healing Pharma India Pvt. Ltd., a GMP-compliant Indian pharmaceutical manufacturer supplying regulated markets including the United States, the United Kingdom, Australia, and Southeast Asia. 

Ivermectin itself is a semisynthetic derivative of avermectin — a natural compound produced by the soil bacterium Streptomyces avermitilis, first isolated in Japan in 1970 by microbiologist Satoshi Ōmura and subsequently developed by William C. Campbell and his team at Merck & Co. The compound was chemically modified to produce Ivermectin — a safer, more potent derivative comprising 80% 22,23-dihydroavermectin-B1a and 20% 22,23-dihydroavermectin-B1b. 

The 6mg strength tablet offers prescribers precision in weight-based dosing — a critical factor given that Ivermectin’s therapeutic dose is calculated per kilogram of body weight. It is available alongside the 3mg and 12mg formulations to enable accurate dosing across a wide patient weight range. 

How Does Iverheal 6mg Work? 

Mechanism of Action 

Ivermectin exerts its antiparasitic effect through a highly selective mechanism. It binds with high affinity to glutamate-gated chloride ion channels (GluCl) found exclusively in the nerve and muscle cells of invertebrates, including parasitic worms and arthropod mites. This binding causes an influx of chloride ions into the cell, leading to hyperpolarization — effectively paralyzing the parasite’s neuromuscular system and causing its death. 

A key safety advantage of this mechanism is that these glutamate-gated chloride channels are absent in mammals, including humans. This selective toxicity explains why Ivermectin is highly effective against parasites while remaining comparatively safe for human use at therapeutic doses. In addition to direct parasite kill, Ivermectin prevents adult female parasites from producing viable larvae, disrupting the reproductive cycle and reducing long-term parasitic burden. 

Pharmacokinetics of Ivermectin 6mg 

Following oral administration on an empty stomach, Ivermectin is absorbed from the gastrointestinal tract, reaching peak plasma concentration within approximately 4 hours. The apparent plasma half-life is approximately 16–18 hours in adults, after which the drug begins to clear from systemic circulation. However, Ivermectin and its metabolites remain pharmacologically active within the intestinal lumen, with excretion via feces continuing for up to 12 days post-dose. Less than 1% of the administered dose is excreted via urine. 

Ivermectin is primarily metabolized in the liver via the CYP3A4 enzyme pathway, and also interacts with the P-glycoprotein (P-gp) transport system — a key consideration for drug interactions (see Drug Interactions section below). 

Bioavailability note: Ivermectin bioavailability increases approximately 2.5-fold when taken with a high-fat meal. For strongyloidiasis and onchocerciasis, the drug is taken on an empty stomach. For scabies and head lice, taking with food may enhance epidermal drug penetration and improve outcomes. 

Uses of Iverheal 6mg 

Iverheal 6mg is prescribed to treat the following parasitic infections, supported by clinical guidelines and regulatory approvals: 

1. Intestinal Strongyloidiasis 

Caused by Strongyloides stercoralis, a parasitic roundworm capable of completing its entire life cycle within a human host (autoinfection), strongyloidiasis can become disseminated and life-threatening in immunocompromised individuals if left untreated. Ivermectin is recognized as the first-line treatment for this condition, demonstrating superior cure rates over alternative agents such as albendazole. A single oral dose of 200 mcg/kg is typically sufficient, with follow-up stool examinations recommended to verify eradication. In immunocompromised patients (including those living with HIV/AIDS), repeated dosing every 2 weeks may be necessary, as WHO guidelines on preventive chemotherapy for strongyloidiasis (2024) acknowledge. 

2. Onchocerciasis (River Blindness) 

Onchocerciasis is caused by Onchocerca volvulus, a filarial worm transmitted by blackfly bites near fast-flowing rivers. It is a leading cause of preventable blindness globally. Iverheal 6mg reduces the microfilarial load in the skin and eyes, alleviating severe pruritus, skin nodules, and progressive vision loss. While Ivermectin does not kill adult worms residing in subcutaneous nodules, it suppresses microfilarial production for 6 to 12 months per dose. Annual or semi-annual dosing is standard within WHO-supported onchocerciasis elimination programmes. 

Critical warning: Ivermectin must NOT be used to treat onchocerciasis in patients co-infected with Loa loa (a filarial parasite endemic to West and Central Africa) due to the risk of potentially fatal encephalopathy in individuals with high Loa loa microfilarial counts. 

3. Lymphatic Filariasis 

Lymphatic filariasis — caused primarily by Wuchereria bancrofti and transmitted by mosquitoes — is targeted for global elimination by the WHO by 2030. Ivermectin plays a central role in the WHO Global Programme to Eliminate Lymphatic Filariasis (GPELF). It is administered in annual mass drug administration (MDA) campaigns, typically as part of a triple-drug regimen combining Ivermectin + Diethylcarbamazine + Albendazole (IDA), which has demonstrated greater efficacy than dual-drug regimens in clinical trials in Papua New Guinea (2022), Haiti, Tanzania (2024), and Nepal (2023–2024). For filariasis, the standard dose is 0.4 mg/kg administered annually 

4. Scabies 

Scabies is caused by the mite Sarcoptes scabiei and presents with intensely pruritic skin lesions. Oral Ivermectin is particularly recommended for crusted (Norwegian) scabies, institutional outbreaks, and cases where topical treatments have failed. A standard dose of 200 mcg/kg is given, with a repeat dose 7–14 days after the first recommended for improved cure rates — as supported by clinical guidance from Next Steps in Dermatology (2025). Side effects are reported in fewer than 4% of patients treated with Ivermectin for skin conditions. 

5. Head Lice (Pediculosis Capitis) 

Oral Ivermectin is an effective therapeutic option for head lice infestations that have shown resistance to topical treatments. It acts by paralyzing the lice and impairing their feeding mechanism. A single oral dose is often effective, though a repeat dose after 7–10 days may be warranted based on clinical response. 

6. Cutaneous Larva Migrans 

This skin condition is caused by hookworm larvae — primarily Ancylostoma braziliense — penetrating the skin from contaminated soil. Ivermectin at 200 mcg/kg administered once daily for 1 to 2 days effectively eliminates the migrating larvae responsible for characteristic serpiginous (winding track-like) skin lesions, as recommended by Médecins Sans Frontières (MSF) medical guidelines. 

7. Mansonella Infections 

Iverheal 6mg is also used in the treatment of filariasis caused by Mansonella ozzardi, Mansonella perstans, and Mansonella streptocerca — parasitic worms transmitted via insect bites in endemic tropical regions. 

 Available Strengths of Iverheal 

• Iverheal 3mg — for patients with lower body weight (15–24 kg) or as a component of multi-tablet dosing 
• Iverheal 6mg — intermediate strength; standard dose for patients weighing 25–44 kg; also used in combination for higher-weight patients 
• Iverheal 12mg — for patients at higher body weights or conditions requiring a larger single dose 

Dosage and Administration of Iverheal 6mg 

Iverheal 6mg dosage is strictly individualized based on the patient’s body weight and the specific parasitic condition being treated. The following table provides weight-based dosage guidelines derived from FDA-approved prescribing information and clinical references: 

Body Weight	Strongyloidiasis	Onchocerciasis	Scabies / Filariasis
25–35 kg	1 tablet (6 mg)	1 tablet (6 mg)	1 tablet (6 mg)
36–50 kg	1.5 tablets (9 mg)	1.5 tablets (9 mg)	2 tablets (12 mg)
51–65 kg	2 tablets (12 mg)	2 tablets (12 mg)	2 tablets (12 mg)
66–79 kg	2.5 tablets (15 mg)	2 tablets (12 mg)	2.5 tablets (15 mg)
≥ 80 kg	0.2 mg/kg	0.15 mg/kg	0.2 mg/kg

Dose calculation reference: Strongyloidiasis = 200 mcg/kg; Onchocerciasis = 150 mcg/kg; Scabies/Filariasis = 200 mcg/kg. For Lymphatic Filariasis in mass drug administration programmes, 400 mcg/kg is the WHO-recommended dose per Drugs.com dosage guidelines (2026). 

Immunocompromised patients (HIV/AIDS): For intestinal strongyloidiasis, repeated treatment every 2 weeks may be required, with monthly suppressive therapy in refractory cases. As noted by Medical News Today (2026), cure may not be fully achievable in severely immunocompromised patients, requiring ongoing monitoring. 

How to Take Iverheal 6mg

• Take on an empty stomach with a full glass of water (approximately 240 mL) for strongyloidiasis and onchocerciasis — at least 1 hour before a meal. 
• For scabies and head lice, taking with food may enhance drug absorption into the skin and improve efficacy. 
• Swallow the tablet whole. Do not crush, chew, or break it unless specifically directed by your healthcare provider. 
• Adhere strictly to the dosing schedule and duration prescribed by your healthcare provider. 
• Carry the medication when travelling to maintain continuity of the treatment schedule. 
• Do not self-adjust doses or discontinue treatment prematurely without consulting a healthcare provider. 

Missed Dose 

If a dose of Iverheal 6mg is missed, take it as soon as it is recalled — provided there is sufficient time before the next scheduled dose. If the next dose is imminent, skip the missed dose entirely and resume the regular schedule. Do not take two doses simultaneously to compensate for a missed one, as this increases the risk of adverse effects without conferring additional therapeutic benefit. 

Overdose 

In the event of an accidental overdose, discontinue the medication and seek medical attention immediately. Symptoms of Ivermectin overdose may include seizures, numbness, tingling, difficulty breathing, loss of consciousness, severe dizziness, muscular weakness, and in severe cases, hypotension and neurological toxicity. Contact your nearest poison control centre or emergency services without delay. Your healthcare provider will manage symptoms based on the dose ingested and clinical presentation. 

Precautions and Warnings 

Before initiating treatment with Iverheal 6mg, it is essential to disclose your complete medical history to your healthcare provider. The following precautions require particular attention: 

Loa loa Co-infection — Critical Warning 

Patients who have lived in or travelled to West or Central Africa may be co-infected with Loa loa (African eye worm). Administration of Ivermectin in individuals with high Loa loa microfilarial counts (above 30,000 mf/mL) is associated with a risk of serious or fatal encephalopathy — a life-threatening brain condition. This represents one of the most critical contraindications for Ivermectin use. Appropriate pre-treatment screening for Loa loa is essential in all at-risk individuals before Iverheal 6mg is prescribed. 

Allergies 

Inform your healthcare provider of any known allergy to Ivermectin or to any inactive excipient in the tablet formulation. Signs of an allergic reaction include skin rash, hives, facial or throat swelling, and difficulty breathing. Discontinue immediately and seek emergency medical care if signs of a severe allergic reaction develop. 

Liver Disease 

Ivermectin is primarily metabolized in the liver via CYP3A4 enzymes. Patients with a history of hepatic impairment or active liver disease should use Iverheal 6mg with caution and under close medical supervision. Periodic assessment of liver function may be appropriate during prolonged therapy. 

Kidney Disease 

While Iverheal 6mg is generally considered lower risk in patients with mild to moderate renal impairment, it is advisable to consult a healthcare provider before initiating therapy in patients with significant kidney disease. 

Immunocompromised Patients 

Patients with compromised immune function — including those living with HIV/AIDS or those on immunosuppressive medications — may require repeated or prolonged courses of Iverheal 6mg. The reduced immune response in these individuals may allow parasitic persistence or autoinfection despite initial treatment. Close clinical follow-up is essential. 

Pregnancy 

Iverheal 6mg is generally not recommended during pregnancy, particularly during the first trimester. A 2020 systematic review and meta-analysis published in The Lancet Global Health (Nicolas et al.) concluded that there is insufficient evidence to confirm the safety of Ivermectin in pregnancy, with very low certainty of evidence regarding risk of spontaneous abortion, stillbirths, or congenital anomalies. Pregnant women are excluded from WHO community-directed treatment programmes for onchocerciasis. Treatment should only be considered when the clinical benefit clearly outweighs potential risk, as assessed by a qualified healthcare provider. 

Breastfeeding 

Ivermectin is excreted into breast milk in small quantities. While published pharmacological data suggest concentrations transferred to the infant are low, breastfeeding is generally not recommended during Iverheal 6mg therapy. Consult a healthcare provider to assess the risk-benefit profile in the context of the specific clinical situation before taking this medication while breastfeeding. 

Asthma and Seizure History 

Patients with a history of asthma or seizure disorders should not use Iverheal 6mg without explicit medical guidance, as the medication may exacerbate these conditions in susceptible individuals. 

Driving and Operating Machinery 

Iverheal 6mg may cause dizziness, drowsiness, and balance disturbances in some patients. It is advisable to refrain from driving, operating heavy machinery, or engaging in tasks requiring full alertness until the individual’s response to the medication has been established. 

Alcohol and Cannabis 

Concurrent use of alcohol or cannabis products during Iverheal 6mg therapy is not advisable. Both substances may potentiate the central nervous system depressant effects of Ivermectin, significantly worsening dizziness and sedation. Patients should abstain from these substances for the duration of treatment. 

Side Effects of Iverheal 6mg 

Like all medications, Iverheal 6mg may cause side effects in some individuals. Clinical evidence indicates that side effects occur in fewer than 4% of patients receiving Ivermectin for cutaneous parasitic conditions. Most side effects are mild, transient, and resolve without medical intervention as the body adjusts to the medication. 

Common (Mild) Side Effects 

The following mild effects have been reported with Iverheal 6mg and generally do not require medical intervention: 

• Dizziness or lightheadedness 
• Nausea or loss of appetite 
• Diarrhea or abdominal discomfort 
• Mild headache 
• Muscle or joint pain 
• Mild skin itching or rash 
• Fatigue or drowsiness 
• Swelling of the lymph nodes (lymphadenopathy) 

Mazzotti Reaction (Onchocerciasis-Specific) 

In approximately 10% of patients treated for onchocerciasis, a Mazzotti reaction may occur — a temporary immunological response triggered by the mass death of microfilariae. This may include worsening skin symptoms (pruritus, rash), mild to moderate fever, joint and limb swelling, and mild eye redness or discomfort. The reaction is generally self-limiting, though severe Mazzotti reactions should be reported to a healthcare provider for appropriate management. 

Serious Side Effects — Seek Immediate Medical Attention

Although uncommon, the following serious adverse effects require prompt discontinuation of Iverheal 6mg and immediate medical attention: 

• Neurological effects: confusion, seizures, difficulty walking or maintaining balance,  encephalopathy, or loss of consciousness 
• Severe respiratory effects: difficulty breathing or shortness of breath 
• Cardiovascular effects: rapid or irregular heartbeat, hypotension (low blood pressure), or fainting 
• Severe ocular effects: significant eye redness, pain, swelling, pus-filled discharge, vision changes, or sudden vision loss 
• Severe cutaneous reactions: extensive blistering, skin peeling, or signs of Stevens-Johnson syndrome 
• Hepatotoxicity: yellowing of the skin or eyes (jaundice), dark-coloured urine, or severe abdominal pain in the upper right quadrant 
• Loss of bladder or bowel control 
• Severe neck or back pain 

If any of the above serious adverse effects are observed, discontinue Iverheal 6mg immediately and seek emergency medical attention without delay. 

Drug Interactions 

Ivermectin is metabolized primarily via the CYP3A4 hepatic enzyme system and is also a substrate of the P-glycoprotein (P-gp) drug transporter. Medications that inhibit or induce either of these pathways may significantly alter Ivermectin plasma concentrations, affecting both its efficacy and safety. The following interactions are clinically relevant: 

High-Priority Interactions 

• Warfarin (anticoagulant): The most clinically significant interaction. Ivermectin may substantially enhance the anticoagulant effect of Warfarin, raising INR values and significantly increasing the risk of dangerous bleeding — even with a single dose of Ivermectin. Patients on Warfarin therapy require close INR monitoring when Iverheal 6mg is introduced or discontinued. Dose adjustment of Warfarin may be necessary. 
• P-glycoprotein inhibitors (e.g., Quinidine, Ritonavir, Itraconazole): These drugs can inhibit P-gp, reducing Ivermectin’s clearance from the CNS and potentially leading to neurological toxicity — including confusion, dizziness, ataxia, and in severe cases, seizures or coma. Avoid co-administration where possible. 
• CYP3A4 inducers (e.g., Oxcarbazepine, Rifampicin): These agents accelerate Ivermectin metabolism, potentially reducing therapeutic plasma concentrations and diminishing treatment efficacy. 
• CYP3A4 inhibitors (e.g., Erythromycin, Ketoconazole, Itraconazole): May inhibit hepatic metabolism of Ivermectin, elevating plasma levels and increasing the risk of adverse effects. 
• HIV protease inhibitors (e.g., Amprenavir, Ritonavir, Lopinavir, Atazanavir): May interfere with Ivermectin’s metabolic pathway via CYP3A4 inhibition, warranting clinical monitoring during concurrent use. 
• CNS depressants (e.g., Benzodiazepines, Barbiturates, Sodium oxybate, Opioids): May potentiate the CNS depressant effects of Ivermectin, increasing sedation and the risk of respiratory depression. 
• Valproic acid: Potential interaction with the CNS-depressant effects of Ivermectin; use with caution. 

Substances to Avoid 

• Alcohol: Concurrent alcohol consumption during Iverheal 6mg therapy significantly intensifies dizziness, drowsiness, and the risk of CNS depression. 
• Grapefruit juice: May inhibit CYP3A4 metabolism in the intestinal wall, potentially increasing Ivermectin plasma levels and adverse effect risk. 

Inform your healthcare provider of all prescription medications, over-the-counter drugs, herbal supplements, and recreational substances currently in use before commencing Iverheal 6mg therapy. 

Clinical Examination and Monitoring 

Prior to initiating Iverheal 6mg, your healthcare provider may recommend the following diagnostic tests to confirm diagnosis and monitor treatment response: 

Stool Examination 

For intestinal strongyloidiasis, stool microscopy is conducted before treatment to confirm the presence of Strongyloides stercoralis larvae and after treatment to verify eradication. The WHO’s 2024 guideline on preventive chemotherapy for strongyloidiasis reinforces the importance of follow-up stool checks to confirm treatment success and detect potential reinfection. 

Skin Snip and Microfilariae Count 

For onchocerciasis, the microfilarial density in skin snips and ocular assessments is measured before and during treatment. A meaningful reduction in microfilarial count is a primary indicator of treatment efficacy. Where counts do not improve adequately after treatment, a dose adjustment or retreatment may be warranted as early as 3 months after the initial dose. 

Pre-Treatment Loa loa Screening 

In patients from Loa loa-endemic regions (West and Central Africa), pre-treatment assessment of Loa loa microfilarial density is strongly recommended before prescribing Iverheal 6mg. Patients with counts above 8,000 mf/mL are at elevated risk for adverse reactions; those with counts above 30,000 mf/mL face a risk of fatal encephalopathy and should not receive Ivermectin without expert clinical supervision and an alternative management plan. 

Liver Function Tests 

In patients with pre-existing hepatic conditions or those requiring prolonged Ivermectin therapy, periodic liver function tests are advisable to monitor for hepatotoxicity and ensure adequate drug metabolism. 

Storage Instructions 

• Store Iverheal 6mg below 30°C (86°F) in a cool, dry environment, protected from direct sunlight, heat, and humidity. 
• Keep the medication in its original packaging, sealed between uses. 
• Store in a location inaccessible to children and pets at all times. 
• Check the expiry date on the packaging before each use. Do not administer medication past its stated shelf life. 
• Do not dispose of unused or expired medication in wastewater or household waste. Consult your pharmacist or local authority for guidance on safe pharmaceutical disposal. 

Common Substitutes for Iverheal 6mg 

If Iverheal 6mg is unavailable, your healthcare provider may consider the following therapeutically equivalent Ivermectin 6mg formulations, subject to medical consultation: 

• Ivertol 6mg Tablet 
• Ivrea 6mg Tablet 
• Ivecop 6mg Tablet 
• Ivernorm 6mg Tablet 
• Wormact 6 Tablet 

Important: Never substitute medications without prior consultation with your healthcare provider or pharmacist, as formulations may differ in inactive ingredients, release profiles, or bioavailability. 

Frequently Asked Questions (FAQs) 

What is Iverheal 6mg used for? 

Iverheal 6mg is prescribed to treat parasitic infections including intestinal strongyloidiasis, onchocerciasis (river blindness), lymphatic filariasis, scabies, cutaneous larva migrans, head lice, and Mansonella infections. It is not approved or recommended for the treatment of COVID-19. 

Is Iverheal 6mg available over the counter? 

No. Iverheal 6mg is a prescription-only medication in most markets. Self-medication with antiparasitic agents is not advisable, as incorrect use may result in treatment failure, drug resistance, or adverse effects. Always obtain a valid prescription from a qualified healthcare provider before purchasing this medication. 

How does Iverheal 6mg work? 

Iverheal 6mg works by selectively binding to glutamate-gated chloride ion channels found only in invertebrate nerve and muscle cells. This binding causes the parasite’s cells to hyperpolarize, resulting in paralysis and death of the organism. It additionally prevents adult female parasites from producing larvae, disrupting the parasite’s reproductive cycle. These ion channels do not exist in mammals, which accounts for the drug’s selective toxicity against parasites. 

Can Iverheal 6mg be taken during pregnancy? 

Iverheal 6mg is generally not recommended during pregnancy, particularly during the first trimester. A landmark systematic review in The Lancet Global Health (Nicolas et al., 2020) found insufficient evidence to confirm safety in pregnancy. Treatment should only be considered when the clinical benefit clearly outweighs potential risk, as determined by a qualified healthcare provider. 

Can I drink alcohol while taking Iverheal 6mg? 

No. Concurrent alcohol use during Iverheal 6mg therapy is not advisable. Alcohol significantly potentiates the CNS depressant effects of Ivermectin, worsening dizziness, sedation, and the risk of falls or accidents. Abstain from alcohol for the duration of treatment. 

How long does it take for Iverheal 6mg to work? 

Ivermectin begins to act within hours of administration, as it is rapidly absorbed with peak plasma levels achieved within approximately 4 hours. Symptomatic relief — such as reduction in itching for scabies — may be noticed within days. However, complete parasite elimination and full clinical resolution may take 1 to 2 weeks depending on the condition treated and parasite burden. 

Can children take Iverheal 6mg? 

Ivermectin tablets are approved for use in children weighing 15 kg or more. Dosage is always determined by body weight. For children below 15 kg, alternative treatments should be discussed with a paediatric healthcare provider. The 6mg tablet formulation is appropriate for children in the 25–44 kg weight range, consistent with FDA-approved dosage guidelines. 

What are the most important drug interactions with Iverheal 6mg? 

The most clinically significant interactions include: Warfarin (increased bleeding risk requiring INR monitoring), P-glycoprotein inhibitors such as Quinidine (risk of CNS toxicity), CYP3A4 inhibitors including Erythromycin, Ketoconazole and Itraconazole (elevated Ivermectin plasma levels), CYP3A4 inducers such as Oxcarbazepine (reduced drug efficacy), and HIV protease inhibitors (metabolic pathway interference). Always disclose all current medications to your healthcare provider before starting Iverheal 6mg. 

What should I do in case of an overdose? 

If you suspect an overdose of Iverheal 6mg, discontinue the medication immediately and contact your nearest poison control centre or emergency medical services. Symptoms such as seizures, numbness, tingling, difficulty breathing, or loss of consciousness require emergency medical attention. 

References

• Drugs.com. (Updated January 2026). Ivermectin: Uses, Dosage, Side Effects, Warnings. https://www.drugs.com/ivermectin.html
• Drugs.com. (Updated January 2026). Ivermectin Dosage Guide + Max Dose, Adjustments. https://www.drugs.com/dosage/ivermectin.html
• Medical News Today. (Updated April 2026). Ivermectin dosage chart: How to take 3-mg oral tablets. https://www.medicalnewstoday.com/articles/drugs-ivermectin-dosage
• Next Steps in Dermatology. (Updated March 2025). Oral Ivermectin Therapeutic Cheat Sheet. https://nextstepsinderm.com/derm-topics/oral-ivermectin-therapeutic-cheat-sheet/
• MedFinder. (Updated June 2026). Ivermectin Drug Interactions: What to Avoid. https://www.medfinder.com/blog/ivermectin-drug-interactions-what-to-avoid-what-to-tell-your-doctor
• LabTestsGuide. (Updated April 2026). Ivermectin Drug Interactions: CYP3A4, P-glycoprotein & Medication Safety. https://www.labtestsguide.com/ivermectin-drug-interactions-what-medications-to-avoid-and-why
• Nicolas P, Maia MF, Bassat Q, et al. (2020). Safety of oral ivermectin during pregnancy: a systematic review and meta-analysis. The Lancet Global Health, 8(1), e92–e100. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7613514/
• Fimbo AM, Mnkugwe RH, Mlugu EM, et al. (2024). Efficacy of ivermectin and albendazole combination in suppressing transmission of lymphatic filariasis following mass administration in Tanzania. Infectious Diseases of Poverty. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11167743/
• PLOS Global Public Health. (2026). Impact of mass drug administration with Ivermectin, Diethylcarbamazine, and Albendazole in elimination of lymphatic filariasis in five districts of Nepal. https://journals.plos.org/globalpublichealth/article?id=10.1371%2Fjournal.pgph.0004809
• PMC / PLoS NTD. (2025). Fixed-dose ivermectin for Mass Drug Administration: Is it time to leave the dose pole behind? Insights from an Individual Participant Data Meta-Analysis. https://pmc.ncbi.nlm.nih.gov/articles/PMC12449026/
• World Health Organization. (2024). Guideline on preventive chemotherapy for public health control of strongyloidiasis. Geneva: WHO. https://www.who.int/publications/i/item/9789240093584
• Médecins Sans Frontières (MSF). (2024). Ivermectin Oral: MSF Medical Guidelines. https://medicalguidelines.msf.org/en/viewport/EssDr/english/ivermectin-oral-16683965.html